metformin has been researched along with Goiter, Nodular in 5 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Goiter, Nodular: An enlarged THYROID GLAND containing multiple nodules (THYROID NODULE), usually resulting from recurrent thyroid HYPERPLASIA and involution over many years to produce the irregular enlargement. Multinodular goiters may be nontoxic or may induce THYROTOXICOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Background Whether metformin might affect the risk of benign nodular goiter in patients with type 2 diabetes mellitus has not been investigated." | 7.91 | Metformin reduces risk of benign nodular goiter in patients with type 2 diabetes mellitus. ( Tseng, CH, 2019) |
| "We investigated the effect of metformin on growth of differentiated human thyroid cells, anaplastic thyroid carcinoma cells, a doxorubicin-resistant thyroid carcinoma cell line, and thyroid cancer stem cells." | 7.78 | Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents. ( Chen, G; Derwahl, M; Renko, K; Xu, S, 2012) |
| "Background Whether metformin might affect the risk of benign nodular goiter in patients with type 2 diabetes mellitus has not been investigated." | 3.91 | Metformin reduces risk of benign nodular goiter in patients with type 2 diabetes mellitus. ( Tseng, CH, 2019) |
| "Objective The study's objective was to evaluate the thyroid parameters in obese insulin-resistant patients with euthyroid diffuse or nodular goiter, following Metformin treatment." | 3.88 | The effect of Metformin treatment in obese insulin-resistant patients with euthyroid goiter. ( Bolboacă, SD; Ghervan, C; Mârza, S; Moga, D; Răcătăianu, N; Sitar-Tăut, AV; Valea, A, 2018) |
| "We investigated the effect of metformin on growth of differentiated human thyroid cells, anaplastic thyroid carcinoma cells, a doxorubicin-resistant thyroid carcinoma cell line, and thyroid cancer stem cells." | 3.78 | Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents. ( Chen, G; Derwahl, M; Renko, K; Xu, S, 2012) |
| "Hearing impairments are the most common symptom of congenital defects, and they generally remain intractable to treatment." | 1.46 | Cochlear Cell Modeling Using Disease-Specific iPSCs Unveils a Degenerative Phenotype and Suggests Treatments for Congenital Progressive Hearing Loss. ( Akamatsu, W; Fujioka, M; Hosoya, M; Matsunaga, T; Ogawa, K; Okamoto, S; Okano, H; Sone, T; Ueda, HR; Ukai, H, 2017) |
| "Eight hundred euthyroid patients with type 2 diabetes (433 women, mean age 65·8 ± 12·5 years) and 671 euthyroid subjects without diabetes were retrospectively evaluated." | 1.40 | An analysis of the relative risk for goitre in euthyroid patients with type 2 diabetes. ( Díez, JJ; Iglesias, P, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Răcătăianu, N | 1 |
| Bolboacă, SD | 1 |
| Sitar-Tăut, AV | 1 |
| Mârza, S | 1 |
| Moga, D | 1 |
| Valea, A | 1 |
| Ghervan, C | 1 |
| Tseng, CH | 1 |
| Díez, JJ | 1 |
| Iglesias, P | 1 |
| Hosoya, M | 1 |
| Fujioka, M | 1 |
| Sone, T | 1 |
| Okamoto, S | 1 |
| Akamatsu, W | 1 |
| Ukai, H | 1 |
| Ueda, HR | 1 |
| Ogawa, K | 1 |
| Matsunaga, T | 1 |
| Okano, H | 1 |
| Chen, G | 1 |
| Xu, S | 1 |
| Renko, K | 1 |
| Derwahl, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Metformin Versus Sitagliptin on Benign Thyroid Nodules Size in Type 2 Diabetes: a 2-years Prospective Multicentric Study[NCT04298684] | Phase 4 | 90 participants (Anticipated) | Interventional | 2021-01-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 other studies available for metformin and Goiter, Nodular
| Article | Year |
|---|---|
The effect of Metformin treatment in obese insulin-resistant patients with euthyroid goiter.
Topics: Adolescent; Adult; Aged; Female; Goiter, Nodular; Humans; Hypoglycemic Agents; Insulin Resistance; M | 2018 |
Metformin reduces risk of benign nodular goiter in patients with type 2 diabetes mellitus.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Goiter, Nodular; Humans; Hypoglycemic Ag | 2019 |
An analysis of the relative risk for goitre in euthyroid patients with type 2 diabetes.
Topics: Aged; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Goiter, Nodular; Humans; Hypoglyce | 2014 |
Cochlear Cell Modeling Using Disease-Specific iPSCs Unveils a Degenerative Phenotype and Suggests Treatments for Congenital Progressive Hearing Loss.
Topics: Adolescent; Adult; Cell Line; Child; Child, Preschool; Cochlea; Female; Goiter, Nodular; Hearing Los | 2017 |
Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents.
Topics: Adenocarcinoma, Follicular; Animals; Antineoplastic Agents; Apoptosis; Carcinoma; Cell Cycle; Cell D | 2012 |